Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Enhances Board Governance
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has introduced new Rules of Procedure for its Board of Directors to enhance corporate governance and protect shareholder interests. This move aims to streamline decision-making and ensure legal compliance, potentially boosting operational efficiency and market position. The company focuses on developing and commercializing bio-pharmaceutical products.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has provided an update.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has established a new set of Rules of Procedure for its Board of Directors, aiming to protect shareholder interests and enhance corporate governance. This initiative is expected to streamline decision-making processes and ensure compliance with relevant legal frameworks, potentially strengthening the company’s operational efficiency and market position.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. operates within the biotechnology and pharmaceutical industry, focusing on the development and commercialization of bio-pharmaceutical products. The company is engaged in innovative research and aims to address significant medical needs through its specialized offerings.
Average Trading Volume: 3,955,670
Current Market Cap: HK$958.4M
